Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance

References

• YoonSBParkJMLimCHChoYKChoiMGEffect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysisHelicobacter201419424324825056262
   PubMed Web of Science ®Google Scholar
• FordACFormanDHuntRHYuanYMoayyediPHelicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trialsBMJ2014348g317424846275
   PubMed Web of Science ®Google Scholar
• FockKMKatelarisPSuganoKSecond asia-pacific consensus guidelines for Helicobacter pylori infectionJ Gastroenterol Hepatol200924101587160019788600
   PubMed Web of Science ®Google Scholar
• KimSGJungHKLeeHLGuidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised editionKorean J Gastroenterol201362132623954956
   PubMedGoogle Scholar
• AsakaMA new approach for elimination of gastric cancer deaths in JapanInt J Cancer201313261272127623180638
   PubMed Web of Science ®Google Scholar
• Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pyloriLiuWZXieYFourth Chinese national consensus report on the management of Helicobacter pylori infectionJ Dig Dis201314521122123302262
   PubMed Web of Science ®Google Scholar
• GhotaslouRLeylabadloHEAslYMPrevalence of antibiotic resistance in Helicobacter pylori: a recent literature reviewWorld J Methodol20155316417426413490
   PubMedGoogle Scholar
• Navarro-JaraboJMFernández-SánchezFFernández-MorenoNPrevalence of primary resistance of Helicobacter pylori to clarithromycin and levofloxacin in Southern SpainDigestion2015922788226227669
   PubMed Web of Science ®Google Scholar
• KuoYTLiouJMEl-OmarEMPrimary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysisLancet Gastroenterol Hepatol201721070771528781119
   PubMed Web of Science ®Google Scholar
• BinhTTShiotaSNguyenLTThe incidence of primary antibiotic resistance of Helicobacter pylori in VietnamJ Clin Gastroenterol201347323323823090037
   PubMed Web of Science ®Google Scholar
• AftabHMiftahussururMSubsomwongPAhmedFKhanAKYamaokaYHelicobacter pylori antibiotic susceptibility patterns in Bangladesh: emerging levofloxacin resistanceJ Infect Dev Ctries201610324525327031456
   PubMed Web of Science ®Google Scholar
• MiftahussururMShresthaPKSubsomwongPSharmaRPYamaokaYEmerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in NepalBMC Microbiol201616125627809767
   PubMed Web of Science ®Google Scholar
• ThungIAraminHVavinskayaVReview article: the global emergence of Helicobacter pylori antibiotic resistanceAliment Pharmacol Ther201643451453326694080
   PubMed Web of Science ®Google Scholar
• PeretzAParitskyMDinisman-ZavulunovEPastukhNGlyatmanTOnASusceptibility of Helicobacter pylori to levofloxacin and rifampicin in IsraelMicrob Drug Resist201521444845125793253
   PubMed Web of Science ®Google Scholar
• LiangCMChengJWKuoCMLevofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practiceBiomed J201437532633025163495
   PubMedGoogle Scholar
• MegraudFCoenenSVersportenAHelicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumptionGut2013621344222580412
   PubMed Web of Science ®Google Scholar
• GisbertJP“Rescue” regimens after Helicobacter pylori treatment failureWorld J Gastroenterol200814355385540218803350
   PubMed Web of Science ®Google Scholar
• MiftahussururMSyamAFNusiIASurveillance of Helicobacter pylori antibiotic susceptibility in indonesia: different resistance types among regions and with novel genetic mutationsPlos One20161112e016619927906990
   PubMed Web of Science ®Google Scholar
• SyamAFMiftahussururMMakmunDRisk factors and prevalence of Helicobacter pylori in five largest islands of indonesia: a preliminary studyPLoS One20151011e014018626599790
   PubMed Web of Science ®Google Scholar
• AbdullahAAAbdullahMFauziASyamAFSimadibrataMMakmunDThe effectiveness of endoscopic retrograde cholangiopancreatography in the management of patients with jaundice at Cipto Mangunkusumo Hospital, JakartaActa Med Indones201244429830323314970
   PubMedGoogle Scholar
• XiaoSDLiuWZXiaDHThe efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori - a randomized double-blind placebo-controlled clinical trialHepatogastroenterology19903755035062253927
   PubMedGoogle Scholar
• BuzásGMJózanJNitrofuran-based regimens for the eradication of Helicobacter pylori infectionJ Gastroenterol Hepatol200722101571158117845685
   PubMed Web of Science ®Google Scholar
• AliBHPharmacology and toxicity of furazolidone in man and animals: some recent researchGen Pharmacol19892055575632691323
   PubMedGoogle Scholar
• KwonDHLeeMKimJJFurazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistanceAntimicrob Agents Chemother200145130630811120984
   PubMed Web of Science ®Google Scholar
• ZhugeLWangYWuSZhaoRLLiZXieYFurazolidone treatment for Helicobacter pylori infection: a systematic review and meta-analysisHelicobacter2018232e1246829480532
   PubMed Web of Science ®Google Scholar
• GisbertJPCastro-FernandezMPerez-AisaAFourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failuresAliment Pharmacol Ther201235894194722372560
   PubMed Web of Science ®Google Scholar
• KuninCMAntimicrobial activity of rifabutinClin Infect Dis199622Suppl_1S3S148785253
   PubMed Web of Science ®Google Scholar
• BrogdenRNFittonARifabutinFARifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacyDrugs199447698310097521834
   PubMed Web of Science ®Google Scholar
• AkadaJKShiraiMFujiiKOkitaKNakazawaTIn vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657Antimicrob Agents Chemother19994351072107610223916
   PubMed Web of Science ®Google Scholar
• HeepMBeckDBayerdörfferELehnNRifampin and rifabutin resistance mechanism in Helicobacter pyloriAntimicrob Agents Chemother19994361497149910348780
   PubMed Web of Science ®Google Scholar
• MiftahussururMYamaokaYAppropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspectiveMolecules20152046068609225856059
   PubMed Web of Science ®Google Scholar
• OgataSKGalesACKawakamiEAntimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusionBraz J Microbiol20144541439144825763052
   PubMed Web of Science ®Google Scholar
• AdachiJADupontHLRifaximin: a novel nonabsorbed rifamycin for gastrointestinal disordersClin Infect Dis200642454154716421799
   PubMed Web of Science ®Google Scholar
• NishizawaTSuzukiHMatsuzakiJHelicobacter pylori resistance to rifabutin in the last 7 yearsAntimicrob Agents Chemother201155115374537521896915
   PubMed Web of Science ®Google Scholar
• MurakamiKOkimotoTKodamaMSitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutationsAntimicrob Agents Chemother20095373097309919380599
   PubMed Web of Science ®Google Scholar
• MalfertheinerPMegraudFO’MorainCAManagement of Helicobacter pylori infection-the Maastricht V/Florence consensus reportGut201766163027707777
   PubMed Web of Science ®Google Scholar
• GohKLNavaratnamPHigh Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in MalaysiaHelicobacter201116324124521585611
   PubMed Web of Science ®Google Scholar
• HuntRHXiaoSDMegraudFHelicobacter pylori in developing countries. world gastroenterology organisation global guidelineJ Gastrointestin Liver Dis201120329930421961099
   PubMed Web of Science ®Google Scholar
• CoelhoLGLeón-BarúaRQuigleyEMLatin-American consensus conference on Helicobacter pylori infection. Latin-American national gastroenterological societies affiliated with the Inter-American Association of Gastroenterology (AIGE)Am J Gastroenterol200095102688269111051336
   PubMed Web of Science ®Google Scholar
• XieYZhuYZhouHFurazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infectionWorld J Gastroenterol20142032114151142125170230
   PubMed Web of Science ®Google Scholar
• De FrancescoVIerardiEHassanCZulloAIs furazolidone therapy for Helicobacter pylori effective and safe?Dig Dis Sci200954102298229919229612
   PubMed Web of Science ®Google Scholar
• JinXTangSChenQFurazolidone induced oxidative DNA damage via up-regulating ROS that caused cell cycle arrest in human hepatoma G2 cellsToxicol Lett2011201320521221195149
   PubMed Web of Science ®Google Scholar
• AliBHPharmacological, therapeutic and toxicological properties of furazolidone: some recent researchVet Res Commun199923634336010543364
   PubMed Web of Science ®Google Scholar
• KoudriakovaTIatsimirskaiaETulebaevSIn vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in ratsJ Pharmacol Exp Ther19962793130013098968354
   PubMed Web of Science ®Google Scholar
• PilottoAFranceschiMRassuMFurlanFScagnelliMIn vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycinAm J Gastroenterol200095383383410710100
   PubMed Web of Science ®Google Scholar
• ToracchioSCapodicasaSSorajaDBCelliniLMarzioLRifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycinDig Liver Dis2005371333815702857
   PubMedGoogle Scholar
• GisbertJPCalvetXReview article: rifabutin in the treatment of refractory Helicobacter pylori infectionAliment Pharmacol Ther201235220922122129228
   PubMed Web of Science ®Google Scholar
• OkumuraRHirataTOnoderaYHoshinoKOtaniTYamamotoTDual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniaeJ Antimicrob Chemother20086219810418390884
   PubMed Web of Science ®Google Scholar
• MatsuzakiJSuzukiHNishizawaTEfficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapiesAntimicrob Agents Chemother20125631643164522203601
   PubMed Web of Science ®Google Scholar
• FujitaKFujitaMItoYPreliminary evaluation of a sitafloxacin-containing regimen for relapsed or refractory pulmonary Mycobacterium avium complex diseaseOpen Forum Infect Dis201633ofw14727704005
   PubMed Web of Science ®Google Scholar
• SuzukiHNishizawaTMuraokaHHibiTSitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutationAntimicrob Agents Chemother20095341720172119188389
   PubMed Web of Science ®Google Scholar
• AkasakaTKurosakaSUchidaYTanakaMSatoKHayakawaIAntibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerasesAntimicrob Agents Chemother1998425128412879593169
   PubMed Web of Science ®Google Scholar
• MoriHSuzukiHMatsuzakiJMasaokaTKanaiTAcquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimensUnited European Gastroenterol J201863391397
   Web of Science ®Google Scholar
• AmburOHDavidsenTFryeSAGenome dynamics in major bacterial pathogensFEMS Microbiol Rev200933345347019396949
   PubMed Web of Science ®Google Scholar
• RamasMDondayMGMcNichollAGGisbertJPEfficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: a phase IV pilot clinical trialGastroenterol Hepatol2017401065866228780968
   PubMed Web of Science ®Google Scholar
• GasbarriniAGasbarriniGPelosiniIScarpignatoCEradication of Helicobacter pylori: are rifaximin-based regimens effective?Digestion200673Suppl 112913516498261
   PubMed Web of Science ®Google Scholar
• ScarpignatoCPelosiniIRifaximin, a poorly absorbed antibiotic: pharmacology and clinical potentialChemotherapy200551Suppl 1366615855748
   PubMed Web of Science ®Google Scholar
• SongMAngTLSecond and third line treatment options for Helicobacter pylori eradicationWorld J Gastroenterol20142061517152824587627
   PubMed Web of Science ®Google Scholar
• KotharyVScherlEJBosworthBRifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumpsAntimicrob Agents Chemother201357281181723183443
   PubMed Web of Science ®Google Scholar
• O’ConnorJRGalangMASambolSPRifampin and rifaximin resistance in clinical isolates of Clostridium difficileAntimicrob Agents Chemother20085282813281718559647
   PubMed Web of Science ®Google Scholar
• HuhulescuSSagelUFiedlerARifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficileJ Med Microbiol201160Pt 81206121221292853
   PubMed Web of Science ®Google Scholar
• ChangJYKimSEKimTHEmergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patientsPLoS One20171210e018612028982166
   PubMed Web of Science ®Google Scholar
• WilliamsDLSpringLCollinsLContribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosisAntimicrob Agents Chemother1998427185318579661035
   PubMed Web of Science ®Google Scholar